CRSP logoCRSP
CRISPR Therapeutics AG

41,101
Loading...
Loading...
News
all
press releases
CRISPR Therapeutics AG (CRSP) Stock Falls Amid Market Uptick: What Investors Need to Know
CRISPR Therapeutics AG (CRSP) reached $67.74 at the closing of the latest trading day, reflecting a -6.98% change compared to its last close.
Zacks·3d ago
News Placeholder
More News
News Placeholder
CRISPR Therapeutics AG (CRSP) Laps the Stock Market: Here's Why
In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $61.67, marking a +2.24% move from the previous day.
Zacks·10d ago
News Placeholder
CRSP & Sirius Begin Dosing in Thromboembolic Disorder Study in EU
CRISPR Therapeutics and Sirius dose the first patient in a phase II study of SRSD107 for thromboembolic disorders in Europe.
Zacks·13d ago
News Placeholder
Is Trending Stock CRISPR Therapeutics AG (CRSP) a Buy Now?
CRISPR Therapeutics (CRSP) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Zacks·13d ago
News Placeholder
3 Promising Genomics & Synthetic Biology Stocks in Spotlight in 2025
GeneDx, Twist Bioscience and Wave Life Sciences are emerging as key players in the fast-growing genomics and synthetic biology space.
Zacks·18d ago
News Placeholder
CRISPR Therapeutics AG (CRSP) Falls More Steeply Than Broader Market: What Investors Need to Know
In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $59.07, marking a -3.46% move from the previous day.
Zacks·19d ago
News Placeholder
Vertex Plunges Around 24% in Six Months: How to Play the Stock
Vertex shares fall nearly 24% in six months on pipeline setbacks but strong CF sales and new launches may shape the future.
Zacks·19d ago
News Placeholder
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching CRISPR Therapeutics (CRSP) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Zacks·24d ago
News Placeholder
Wall Street Analysts See CRISPR Therapeutics (CRSP) as a Buy: Should You Invest?
Based on the average brokerage recommendation (ABR), CRISPR Therapeutics (CRSP) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
Zacks·25d ago
News Placeholder
CRISPR Therapeutics AG (CRSP) Stock Slides as Market Rises: Facts to Know Before You Trade
In the most recent trading session, CRISPR Therapeutics AG (CRSP) closed at $51.81, indicating a -3.5% shift from the previous trading day.
Zacks·26d ago

Latest CRSP News

View

Advertisement|Remove ads.

Advertisement|Remove ads.